Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study.
D MoneyT LeeC O'BrienJ BrophyA BitnunF KakkarI BoucoiranA AlimentiW VaudryJ SingerLaura J Sauvenull nullPublished in: BJOG : an international journal of obstetrics and gynaecology (2019)
Five percent of the infants of Canadian women living with HIV on dolutegravir at conception had congenital anomalies; none had neural tube defects.